

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Valenzuela *et al.*

Application No. 10/527,500

Filed: March 11, 2005

Confirmation No. 9994

For: P. ARIASI POLYPEPTIDES, P. PERNICIOSUS
POLYPEPTIDES AND METHODS OF USE

FILED VIA EFS

Examiner: Nina Archie

Art Unit: 1645

Attorney Reference No. 4239-66903-02

FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and submitted herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301
cc: Docketing

KLARQUIST SPARKMAN, LLP

By /Anne Carlson/
Anne Carlson, Ph.D.
Registration No. 47,472